Loading
Led CheckMate 577, the first trial to show adjuvant immunotherapy helps oesophageal cancer patients with residual disease.
Ronan Kelly (Baylor Sammons Cancer Center) was principal investigator of CheckMate 577, which showed adjuvant nivolumab doubles disease-free survival in oesophageal and junctional cancer patients with residual disease after chemoradiotherapy and surgery, the first adjuvant immunotherapy approval in a GI cancer. He continues to lead perioperative immunotherapy trials in upper GI cancers.
| Title | Journal | Year |
|---|---|---|
| Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (CheckMate 577) | NEJM | 2021 |
| Emerging multimodality approaches to treat localized esophageal cancer | Journal of the National Comprehensive Cancer Network | 2019 |
Shares Oesophageal cancer, Nivolumab, PD-1, Gastric & gastro-oesophageal junction cancer and the tags esophageal, immunotherapy.
Shares Oesophageal cancer, Nivolumab, PD-1, Immune checkpoint inhibitors and the tags esophageal, immunotherapy.
Shares Nivolumab, PD-1, Immune checkpoint inhibitors and the tags immunotherapy, adjuvant.
Shares Nivolumab, PD-1, Immune checkpoint inhibitors and the tags immunotherapy, adjuvant.
Shares PD-1 and the tags immunotherapy, adjuvant.
Shares Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.